IGHV1-68

Across TCGA pan-cancer cohorts, IGHV1-68 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGHV1-68 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher IGHV1-68 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV1-68 expression acts as an unfavorable survival marker.

ACC are the cancer types where IGHV1-68 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

IGHV1-68–ACC (DFS)

Open the ACC breakdown →